UNITED THERAPEUTICS CORP (UTHR) Fundamental Analysis & Valuation

NASDAQ:UTHR • US91307C1027

Current stock price

570.4 USD
-0.95 (-0.17%)
At close:
570.4 USD
0 (0%)
After Hours:

This UTHR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. UTHR Profitability Analysis

1.1 Basic Checks

  • In the past year UTHR was profitable.
  • In the past year UTHR had a positive cash flow from operations.
  • Each year in the past 5 years UTHR has been profitable.
  • In the past 5 years UTHR always reported a positive cash flow from operatings.
UTHR Yearly Net Income VS EBIT VS OCF VS FCFUTHR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

1.2 Ratios

  • UTHR has a Return On Assets of 16.94%. This is amongst the best in the industry. UTHR outperforms 95.54% of its industry peers.
  • UTHR has a better Return On Equity (18.81%) than 94.77% of its industry peers.
  • UTHR has a better Return On Invested Capital (16.10%) than 95.93% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for UTHR is significantly below the industry average of 28.06%.
  • The last Return On Invested Capital (16.10%) for UTHR is above the 3 year average (15.88%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 16.94%
ROE 18.81%
ROIC 16.1%
ROA(3y)15.64%
ROA(5y)13.63%
ROE(3y)17.94%
ROE(5y)16.2%
ROIC(3y)15.88%
ROIC(5y)14.43%
UTHR Yearly ROA, ROE, ROICUTHR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

1.3 Margins

  • UTHR has a Profit Margin of 41.94%. This is amongst the best in the industry. UTHR outperforms 97.29% of its industry peers.
  • In the last couple of years the Profit Margin of UTHR has grown nicely.
  • The Operating Margin of UTHR (47.63%) is better than 99.22% of its industry peers.
  • In the last couple of years the Operating Margin of UTHR has grown nicely.
  • UTHR's Gross Margin of 87.92% is amongst the best of the industry. UTHR outperforms 88.95% of its industry peers.
  • In the last couple of years the Gross Margin of UTHR has remained more or less at the same level.
Industry RankSector Rank
OM 47.63%
PM (TTM) 41.94%
GM 87.92%
OM growth 3Y-2.34%
OM growth 5Y3.56%
PM growth 3Y3.74%
PM growth 5Y3.86%
GM growth 3Y-1.56%
GM growth 5Y-1.06%
UTHR Yearly Profit, Operating, Gross MarginsUTHR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. UTHR Health Analysis

2.1 Basic Checks

  • UTHR has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, UTHR has less shares outstanding
  • Compared to 5 years ago, UTHR has less shares outstanding
  • UTHR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
UTHR Yearly Shares OutstandingUTHR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
UTHR Yearly Total Debt VS Total AssetsUTHR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 22.18 indicates that UTHR is not in any danger for bankruptcy at the moment.
  • UTHR has a better Altman-Z score (22.18) than 89.53% of its industry peers.
  • UTHR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 22.18
ROIC/WACC1.7
WACC9.5%
UTHR Yearly LT Debt VS Equity VS FCFUTHR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B

2.3 Liquidity

  • A Current Ratio of 6.60 indicates that UTHR has no problem at all paying its short term obligations.
  • UTHR's Current ratio of 6.60 is fine compared to the rest of the industry. UTHR outperforms 65.31% of its industry peers.
  • A Quick Ratio of 6.28 indicates that UTHR has no problem at all paying its short term obligations.
  • UTHR has a Quick ratio of 6.28. This is in the better half of the industry: UTHR outperforms 64.15% of its industry peers.
Industry RankSector Rank
Current Ratio 6.6
Quick Ratio 6.28
UTHR Yearly Current Assets VS Current LiabilitesUTHR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. UTHR Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 13.41% over the past year.
  • UTHR shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 19.23% yearly.
  • UTHR shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.61%.
  • Measured over the past years, UTHR shows a quite strong growth in Revenue. The Revenue has been growing by 16.50% on average per year.
EPS 1Y (TTM)13.41%
EPS 3Y22.93%
EPS 5Y19.23%
EPS Q2Q%24.39%
Revenue 1Y (TTM)10.61%
Revenue growth 3Y18.02%
Revenue growth 5Y16.5%
Sales Q2Q%7.38%

3.2 Future

  • The Earnings Per Share is expected to grow by 14.14% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 14.18% on average over the next years. This is quite good.
EPS Next Y4.76%
EPS Next 2Y11.22%
EPS Next 3Y12.44%
EPS Next 5Y14.14%
Revenue Next Year3.67%
Revenue Next 2Y8.8%
Revenue Next 3Y11.06%
Revenue Next 5Y14.18%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
UTHR Yearly Revenue VS EstimatesUTHR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
UTHR Yearly EPS VS EstimatesUTHR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30 40 50

More info and screens

Find the best growth stocksShow best growing peers

6

4. UTHR Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 20.44 indicates a rather expensive valuation of UTHR.
  • 93.02% of the companies in the same industry are more expensive than UTHR, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of UTHR to the average of the S&P500 Index (26.64), we can say UTHR is valued slightly cheaper.
  • With a Price/Forward Earnings ratio of 19.52, UTHR is valued on the expensive side.
  • UTHR's Price/Forward Earnings ratio is rather cheap when compared to the industry. UTHR is cheaper than 94.38% of the companies in the same industry.
  • UTHR's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 21.36.
Industry RankSector Rank
PE 20.44
Fwd PE 19.52
UTHR Price Earnings VS Forward Price EarningsUTHR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

  • 94.57% of the companies in the same industry are more expensive than UTHR, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, UTHR is valued cheaper than 94.38% of the companies in the same industry.
Industry RankSector Rank
P/FCF 24.15
EV/EBITDA 12.94
UTHR Per share dataUTHR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The excellent profitability rating of UTHR may justify a higher PE ratio.
  • UTHR's earnings are expected to grow with 12.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.3
PEG (5Y)1.06
EPS Next 2Y11.22%
EPS Next 3Y12.44%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. UTHR Dividend Analysis

5.1 Amount

  • No dividends for UTHR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

UTHR Fundamentals: All Metrics, Ratios and Statistics

UNITED THERAPEUTICS CORP

NASDAQ:UTHR (5/1/2026, 8:01:07 PM)

After market: 570.4 0 (0%)

570.4

-0.95 (-0.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)02-25
Earnings (Next)05-06
Inst Owners97.31%
Inst Owner Change0.18%
Ins Owners1.94%
Ins Owner Change32.81%
Market Cap25.00B
Revenue(TTM)3.18B
Net Income(TTM)1.33B
Analysts81.9
Price Target648.1 (13.62%)
Short Float %6.31%
Short Ratio4.71
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.35%
Min EPS beat(2)-2.35%
Max EPS beat(2)5.05%
EPS beat(4)1
Avg EPS beat(4)-1.8%
Min EPS beat(4)-9.46%
Max EPS beat(4)5.05%
EPS beat(8)2
Avg EPS beat(8)-2.1%
EPS beat(12)6
Avg EPS beat(12)0.77%
EPS beat(16)8
Avg EPS beat(16)-0.29%
Revenue beat(2)0
Avg Revenue beat(2)-4.27%
Min Revenue beat(2)-4.72%
Max Revenue beat(2)-3.81%
Revenue beat(4)1
Avg Revenue beat(4)-1.12%
Min Revenue beat(4)-4.72%
Max Revenue beat(4)6.71%
Revenue beat(8)4
Avg Revenue beat(8)0.39%
Revenue beat(12)7
Avg Revenue beat(12)1.48%
Revenue beat(16)9
Avg Revenue beat(16)1.26%
PT rev (1m)7.46%
PT rev (3m)20.07%
EPS NQ rev (1m)0.38%
EPS NQ rev (3m)-4.85%
EPS NY rev (1m)-2.15%
EPS NY rev (3m)-0.82%
Revenue NQ rev (1m)-1.21%
Revenue NQ rev (3m)-2.57%
Revenue NY rev (1m)-0.65%
Revenue NY rev (3m)-2%
Valuation
Industry RankSector Rank
PE 20.44
Fwd PE 19.52
P/S 7.86
P/FCF 24.15
P/OCF 16.01
P/B 3.52
P/tB 3.58
EV/EBITDA 12.94
EPS(TTM)27.9
EY4.89%
EPS(NY)29.23
Fwd EY5.12%
FCF(TTM)23.62
FCFY4.14%
OCF(TTM)35.62
OCFY6.24%
SpS72.61
BVpS161.9
TBVpS159.25
PEG (NY)4.3
PEG (5Y)1.06
Graham Number318.802 (-44.11%)
Profitability
Industry RankSector Rank
ROA 16.94%
ROE 18.81%
ROCE 20.71%
ROIC 16.1%
ROICexc 26.8%
ROICexgc 27.52%
OM 47.63%
PM (TTM) 41.94%
GM 87.92%
FCFM 32.53%
ROA(3y)15.64%
ROA(5y)13.63%
ROE(3y)17.94%
ROE(5y)16.2%
ROIC(3y)15.88%
ROIC(5y)14.43%
ROICexc(3y)29.26%
ROICexc(5y)26.59%
ROICexgc(3y)30.21%
ROICexgc(5y)27.3%
ROCE(3y)20.42%
ROCE(5y)18.56%
ROICexgc growth 3Y0.25%
ROICexgc growth 5Y6.53%
ROICexc growth 3Y-0.12%
ROICexc growth 5Y7.38%
OM growth 3Y-2.34%
OM growth 5Y3.56%
PM growth 3Y3.74%
PM growth 5Y3.86%
GM growth 3Y-1.56%
GM growth 5Y-1.06%
F-Score8
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 614.49%
Cap/Sales 16.53%
Interest Coverage 112.28
Cash Conversion 97.49%
Profit Quality 77.56%
Current Ratio 6.6
Quick Ratio 6.28
Altman-Z 22.18
F-Score8
WACC9.5%
ROIC/WACC1.7
Cap/Depr(3y)462.52%
Cap/Depr(5y)380.04%
Cap/Sales(3y)11.66%
Cap/Sales(5y)9.87%
Profit Quality(3y)81.3%
Profit Quality(5y)87.1%
High Growth Momentum
Growth
EPS 1Y (TTM)13.41%
EPS 3Y22.93%
EPS 5Y19.23%
EPS Q2Q%24.39%
EPS Next Y4.76%
EPS Next 2Y11.22%
EPS Next 3Y12.44%
EPS Next 5Y14.14%
Revenue 1Y (TTM)10.61%
Revenue growth 3Y18.02%
Revenue growth 5Y16.5%
Sales Q2Q%7.38%
Revenue Next Year3.67%
Revenue Next 2Y8.8%
Revenue Next 3Y11.06%
Revenue Next 5Y14.18%
EBIT growth 1Y4.68%
EBIT growth 3Y15.26%
EBIT growth 5Y20.65%
EBIT Next Year9.4%
EBIT Next 3Y14.92%
EBIT Next 5Y-7.27%
FCF growth 1Y-4.2%
FCF growth 3Y15.97%
FCF growth 5Y8.25%
OCF growth 1Y17.64%
OCF growth 3Y24.84%
OCF growth 5Y15.62%

UNITED THERAPEUTICS CORP / UTHR Fundamental Analysis FAQ

What is the fundamental rating for UTHR stock?

ChartMill assigns a fundamental rating of 7 / 10 to UTHR.


What is the valuation status of UNITED THERAPEUTICS CORP (UTHR) stock?

ChartMill assigns a valuation rating of 6 / 10 to UNITED THERAPEUTICS CORP (UTHR). This can be considered as Fairly Valued.


How profitable is UNITED THERAPEUTICS CORP (UTHR) stock?

UNITED THERAPEUTICS CORP (UTHR) has a profitability rating of 9 / 10.


Can you provide the PE and PB ratios for UTHR stock?

The Price/Earnings (PE) ratio for UNITED THERAPEUTICS CORP (UTHR) is 20.44 and the Price/Book (PB) ratio is 3.52.